Imperial College London
Portrait Picture

Dr Fu Siong Ng

Faculty of Medicine, National Heart & Lung Institute

Reader in Cardiac Electrophysiology
 
 
 
//

Contact

 

+44 (0)20 7594 3614f.ng Website

 
 
//

Location

 

430ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ng:2021:10.1016/j.jacep.2020.12.014,
author = {Ng, FS and Toman, O and Petru, J and Peichl, P and Winkle, RA and Reddy, VY and Neuzil, P and Mead, RH and Qureshi, NA and Whinnett, ZI and Bourn, DW and Shelton, MB and Kautzner, J and Sharma, AD and Hocini, M and Haïssaguerre, M and Peters, NS and Efimov, IR},
doi = {10.1016/j.jacep.2020.12.014},
journal = {JACC: Clinical Electrophysiology},
pages = {988--999},
title = {Novel low-voltage multiPulse therapy to terminate atrial fibrillation.},
url = {http://dx.doi.org/10.1016/j.jacep.2020.12.014},
volume = {7},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - OBJECTIVES: This first-in-human feasibility study was undertaken to translate the novel low-voltage MultiPulse Therapy (MPT) (Cardialen, Inc., Minneapolis, Minnesota), which was previously been shown to be effective in preclinical studies in terminating atrial fibrillation (AF), into clinical use. BACKGROUND: Current treatment options for AF, the most common arrhythmia in clinical practice, have limited success. Previous attempts at treating AF by using implantable devices have been limited by the painful nature of high-voltage shocks. METHODS: Forty-two patients undergoing AF ablation were recruited at 6 investigational centers worldwide. Before ablation, electrode catheters were placed in the coronary sinus, right and/or left atrium, for recording and stimulation. After the induction of AF, MPT, which consists of up to a 3-stage sequence of far- and near-field stimulation pulses of varied amplitude, duration, and interpulse timing, was delivered via temporary intracardiac leads. MPT parameters and delivery methods were iteratively optimized. RESULTS: In the 14 patients from the efficacy phase, MPT terminated 37 of 52 (71%) of AF episodes, with the lowest median energy of 0.36 J (interquartile range [IQR]: 0.14 to 1.21 J) and voltage of 42.5 V (IQR: 25 to 75 V). Overall, 38% of AF terminations occurred within 2 seconds of MPT delivery (p < 0.0001). Shorter time between AF induction and MPT predicted success of MPT in terminating AF (p < 0.001). CONCLUSIONS: MPT effectively terminated AF at voltages and energies known to be well tolerated or painless in some patients. Our results support further studies of the concept of implanted devices for early AF conversion to reduce AF burden, symptoms, and progression.
AU  - Ng,FS
AU  - Toman,O
AU  - Petru,J
AU  - Peichl,P
AU  - Winkle,RA
AU  - Reddy,VY
AU  - Neuzil,P
AU  - Mead,RH
AU  - Qureshi,NA
AU  - Whinnett,ZI
AU  - Bourn,DW
AU  - Shelton,MB
AU  - Kautzner,J
AU  - Sharma,AD
AU  - Hocini,M
AU  - Haïssaguerre,M
AU  - Peters,NS
AU  - Efimov,IR
DO  - 10.1016/j.jacep.2020.12.014
EP  - 999
PY  - 2021///
SN  - 2405-5018
SP  - 988
TI  - Novel low-voltage multiPulse therapy to terminate atrial fibrillation.
T2  - JACC: Clinical Electrophysiology
UR  - http://dx.doi.org/10.1016/j.jacep.2020.12.014
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33812836
UR  - https://www.sciencedirect.com/science/article/pii/S2405500X21000177?via%3Dihub
UR  - http://hdl.handle.net/10044/1/91406
VL  - 7
ER  -
Download